Janssen Takes A Step Closer To A Universal Flu Vaccine
This article was originally published in Scrip
Scientists at Janssen (Johnson & Johnson, formerly Crucell Vaccine Institute) have found a way to induce antibodies that could lead to the development of an effective universal flu vaccine and eliminate the need for annual injections.
You may also be interested in...
Cidara partners its antiviral conjugate platform for seasonal and pandemic influenza with Janssen, which also gets option rights to an AVC candidate for respiratory syncytial virus.
Last week, the Swiss major gave a glimpse into the next wave of innovation coming out of its labs in key areas such as osteoarthritis, pancreatic cancer and food allergy. Scrip has been taking a detailed look at the highlights.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.